ArticleInternational journal of clinical oncology2025
Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival benefit of combining chemotherapy (chemo) with immune checkpoint inhibitors (ICIs) in older patients with advanced non-small cell lung cancer (NSCLC) remains unclear. We evaluated the lung immune prognostic index (LIPI) as a predictive biomarker in this NEJ057 secondary analysis.
methodsThis analysis included 600 patients aged ≥ 75 years with NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1% enrolled in the NEJ057 study. LIPI was categorized as good, intermediate, or poor based on derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and multivariate Cox proportional hazards models. Subgroup analyses focused on patients with a PD-L1 TPS of 1-49% and intermediate/poor LIPI to evaluate predictive factors for ICI-chemo benefit.
resultsThe survival outcomes of ICI-chemo and ICI-alone varied across different patient characteristics, with LIPI identified as a predictive biomarker. Among patients with a PD-L1 TPS of 1-49% and intermediate/poor LIPI scores, ICI-chemo was associated with significantly longer OS (median: 18.3 months [95% confidence interval {CI} 10.7-26.7] vs. 8.6 months [95% CI 4.5-12.4], p = 0.007; hazard ratio [HR]: 0.56 [95% CI 0.36-0.86]) and PFS (median: 7.8 months [95% CI 6.2-9.7] vs. 3.3 months [95% CI 1.5-5.0], p = 0.002; HR: 0.56 [95% CI 0.39-0.81]) compared with ICI-alone. No significant survival benefit was observed in patients with a PD-L1 TPS of ≥ 50% or good LIPI scores.
conclusionsLIPI is a useful biomarker for guiding treatment decisions in older patients with NSCLC and a PD-L1 TPS of 1-49%, particularly those with intermediate/poor LIPI scores. Its application might facilitate establishing more personalized strategies and improve outcomes.
Indexed as
Identifiers
41191235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.